Clinical trial NCT05648136: Immune Profile Analysis and Biomarker Identification in Women With Repeated Implantation Failure or Unexplained Recurrent Spontaneous Miscarriage
Official title: Immune Profile Analysis and Biomarker Identification in Women With Repeated Implantation Failure or Unexplained Recurrent Spontaneous Miscarriage
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Repeated Embryo Implantation Failure
Recurrent Miscarriage
Immune System
Keywords: repeated embryo implantation failure
recurrent spontaneous miscarriage
immunological analysis
immune system
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2022-12-13
Enrollment: 150
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 39
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Implantation is a determining step in human reproduction which requires the transition from a pro-inflammatory state to an anti-inflammatory state allowing the implantation of a competent embryo within a receptive endometrium, and then the maternal immunotolerance towards the alloantigenic fetus. Repeat implantation failures (RIFs), that refers to the fail to achieve a clinical pregnancy after the transfer of at least 3-4 good quality embryos or two blastocysts, and unexplained recurrent spontaneous miscarriage (RM) (≥2-3) could be related in some patients to immune imbalances characterized by an excessive and prolonged inflammatory response and/or a defect of anti-inflammatory regulation. In this context, several therapies have been evaluated in patients with RIFs or RMs in order to restore the immune balance, with heterogeneous results. No serum biomarker assay has been routinely approved to identify patients with immune imbalances that may explain repeated pregnancy failures and to predict the success of the subsequent IVF/ICSI cycle. The immunological analysis on peripheral blood will be based on the determination of the proportions of immune subpopulations (e.g. CD4+ et CD8+, TH1, TH2, TH17, Treg, ILC 1, ILC2, and ILC3) on the one hand and the circulating level of plasma cytokines on the other hand.


Eligibility criteria: Inclusion Criteria:

* For patients :
* Women aged 18 to 39 years
* women with a history of RIF or unexplained RM
* women with a negative diagnostic work-up (including pelvic ultrasound and hysteroscopy, parental karyotype, thyroid function test, and anti-thyroid and anti-phospholipid antibodies)
* women with a basal FSH level \<10IU/l and AMH level \>1.5ng/ml
* women with a regular menstrual cycle of 30+/-5 days
* women receiving a new cycle of in vitro fertilization (IVF) +/- intracytoplasmic sperm injection (ICSI) for patients in the RIF group or a first cycle of IVF +/-ICSI for patients in the RM group
* women received written and oral information and signed an informed consent

For control groups:

* Controls recruited in the Obstetrics and Gynecology Department with at least one live birth after a spontaneous pregnancy (with a time to conception of less than 12 months for each pregnancy) Voluntary oocyte donors recruited within the CECOS de Picardie (having presented at least one live birth with a delay necessary to conceive of less than 12 months)
* Controls recruited in the Reproductive Medicine and Biology Department having presented at least one live birth (spontaneous with a delay to conceive of less than 12 months for each pregnancy or after one or two MPA procedures) and benefiting from an IVF+/-ICSI procedure for secondary infertility
* Controls recruited in the department of Medicine and Reproductive Biology with a normal infertility assessment and benefiting from an IVF procedure with ICSI on male indication.

Exclusion Criteria:

* Ongoing pelvic and/or systemic infection
* Chronic infectious endometritis
* Active neoplasia
* Autoimmune and autoinflammatory disease
* Celiac disease
* Thrombophilia (including positive anti-phospholipid antibodies)
* Endocrine pathology (including dysthyroidism and diabetes)
* Endometriosis
* Polycystic ovary syndrome and ovulatory disorders
* Premature ovarian failure
* IVF by oocyte donation
* Tubal obstructions or lesions, uterine and cervical anomalies
* Partners with extreme oligoastheno-spermia and/or sperm DNA fragmentation \>30
* Sperm donations
* Patients unable to give informed consent

Primary outcomes:
measure: Variation of the proportion of CD4+ subpopulations between both patient groups
timeFrame: 18 months
measure: Variation of the proportion of CD8+ subpopulations between both patient groups
timeFrame: 18 months
measure: Variation of the proportion of TH1 subpopulations between both patient groups
timeFrame: 18 months
measure: Variation of the proportion of TH2 subpopulations between both patient groups
timeFrame: 18 months
measure: Variation of the proportion of TH17 subpopulations between both patient groups
timeFrame: 18 months
measure: Variation of the proportion of Treg subpopulations between both patient groups
timeFrame: 18 months
measure: Variation of the proportion of ILC 1 subpopulations between both patient groups
timeFrame: 18 months
measure: Variation of the proportion of ILC 2 subpopulations between both patient groups
timeFrame: 18 months
measure: Variation of the proportion of ILC 3 subpopulations between both patient groups
timeFrame: 18 months
measure: Variation of the proportion of TNFα concentrations between both patient groups
timeFrame: 18 months
measure: Variation of the proportion of IFN gamma concentrations between both patient groups
timeFrame: 18 months
measure: Variation of the proportion of TGF-β concentrations between both patient groups
timeFrame: 18 months
measure: Variation of the proportion of IL-10 concentrations between both patient groups
timeFrame: 18 months
measure: Variation of the proportion of IL-17 concentrations between both patient groups
timeFrame: 18 months
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: Centre Hospitalier Universitaire d'Amiens
state: Picardie
Study officials:
References: